Validation of a Portable Medical Device for Diagnostic in Vitro

NCT ID: NCT02843958

Last Updated: 2016-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is about a new technology, named HEMOPTIC. It enables to mesure time of blood coagulation for monitoring of patients under Vitamin K antagonist (VKA).

This device was created as an alternative to blood sample, that have to be done in a medical laboratory.

The main goal is to evaluate the accuracy of the International Normalized Ratio (INR) measurement of this new portable device for diagnostic in vitro, among healthy patients and patients under anti-vitamin K treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer Patients Under Vitamin K Antagonist (VKA)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Medical device Hemoptic Vitamin K antagonist Diagnostic in vitro

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers and patients under Vitamin K antagonist

Group Type OTHER

HEMOPTIC

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HEMOPTIC

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman between 18 and 70 years
* Body Mass Index \>18 and \<29
* Absence of any acute pathology in the month preceding the study
* To be affiliated or beneficiary of social security


* Man or woman between 18 and 80 years
* Patient treated by oral anti vitamin K anticoagulants (coumadine, warfarine, fluidione)
* Absence of any acute pathology in the month preceding the study
* To be affiliated or beneficiary of social security

Exclusion Criteria

* Pregnant, partutient or breastfeeding woman
* Patient with Raynaud's syndrome
* Person deprived of liberty by legal or administrative decision, person to a legal protection order
* Deferral periods for other clinical studies
* Annual threshold compensation attain for biomedical search participations


* Pregnant, partutient or breastfeeding woman
* Patient with Raynaud's syndrome
* Person deprived of liberty by legal or administrative decision, person to a legal protection order
* Deferral periods for other clinical studies
* Annual threshold compensation attain for biomedical search participations
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Luc Cracowski, Professor

Role: PRINCIPAL_INVESTIGATOR

Grenoble Hospital University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UniversityHospitalGrenoble

La Tronche, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006 Feb 4;367(9508):404-11. doi: 10.1016/S0140-6736(06)68139-7.

Reference Type BACKGROUND
PMID: 16458764 (View on PubMed)

Faivre M, Peltie P, Planat-Chretien A, Cosnier ML, Cubizolles M, Nougier C, Negrier C, Pouteau P. Coagulation dynamics of a blood sample by multiple scattering analysis. J Biomed Opt. 2011 May;16(5):057001. doi: 10.1117/1.3573813.

Reference Type BACKGROUND
PMID: 21639579 (View on PubMed)

Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010 Oct 21;363(17):1608-20. doi: 10.1056/NEJMoa1002617.

Reference Type BACKGROUND
PMID: 20961244 (View on PubMed)

McBride GB (2005) A proposal for strength-of-agreement criteria for Lin's Concordance Correlation Coefficient. NIWA Client Report: HAM2005-062.

Reference Type BACKGROUND

Riberolles, C. (2009). Résultats du PHRC autocontôle de l'anticoagulation. Conférence. XIXes Journées européennes de la Société française de cardiologie, Paris.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

38RC14.008

Identifier Type: -

Identifier Source: org_study_id